Life Science News

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFD) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that the Silo Wellness team coordinated the presentations of eight speakers in support of psilocybin use under Ballot Measure 109 in Lane County, Oregon, (Oregon's largest county by population outside the Portland metro area) at Tuesday's public board of commissioners meeting.

"It is important that Silo Wellness help support the education of local governments and law enforcement, as we are the only Oregon-based publicly traded psychedelics company and the only Oregon-based company with experience providing legal psilocybin use [in Jamaica] through our psychedelic wellness retreats," stated Silo Wellness founder, a Lane County, Oregon, resident since 1998. "We want to prevent any misinformation comparing the roll out of this service-based wellness industry to any perceived mishaps from Oregon's experience in the cannabis space, particularly regarding diversion and impact on neighbors." In written testimony provided to the Board, Mr. Arnold explained that currently Silo Wellness is in advanced negotiations with property owners outside of unincorporated Lane County and didn't technically "have a dog in this fight" at this time.

On Monday, the Lane County Board of Commissioners placed on Tuesday's agenda potential actions on Ballot Measure 109, including the possibility of referring an "optout" ballot measure to the voters, who already voted 60% in favor of Oregon's regulated psilocybin program in 2020. After the Silo team's public comment, Springfield commissioner Joe Berney stated, "I was really persuaded by the testimony this morning from public comment. I was persuaded by compassionate use that this is therapy, and the regulatory framework is being developed." He went on to explain that he was on the side of "'doing nothing [to prevent implementation of BM109] as the voters of Lane County requested." Thereafter, the commissioners unanimously declined to refer this issue to a vote and instead requested that staff provide a report on potential time, manner, and use restrictions.

Silo Wellness organized seven additional experts and advocates in the psychedelic space including: Dr. Joshua Siegel, M.D., Ph.D, of Washington University's Program in Psychedelic Research in St. Louis, Missouri; Dr. Parag Bhatt, Ph.D., of St. Louis, pharmacologist and Silo Wellness's retreat intake coordinator; Josh Wilson of St. Joseph, Missouri, Silo's retreat customer success manager; Frank Cartwright, of London, U.K., impact investment manager and mental health advocate; Greg Biniowsky, a Vancouver, British Columbia lawyer and a Silo independent board member and audit committee member; Heather Lee of Colorado, a licensed social worker (Colorado/Oregon) and psychedelic practitioner with emphasis in cancer/end-of-life issues; and Nimi Gandhi, of Miami, Florida, marketing/creative specialist and ADHD/anxiety psilocybin success story.

The presentations to the Board were educational and impactful. Dr. Siegel explained that psilocybin is not physically addictive and has little risk of toxicity. He stated that caffeine is an order of magnitude of 10 more toxic than psilocybin, and alcohol is 100 times more toxic than psilocybin. Dr. Bhatt and Josh Wilson both discussed their experiences interacting with Silo Wellness psilocybin retreat participants and how lives are changed positively. Mr. Biniowsky commented on how he started off as a skeptic seeing "magic mushrooms" as a recreational drug but has been blown away by the scientific research and from what he has seen in his role as an advisor to Silo's retreat team, focusing on regulatory compliance and best practices.

Heather Lee gave a passionate and impactful personal story of psilocybin and how she came to terms with her recent breast cancer diagnosis. Ms. Gandhi gave a personal anecdote of how psilocybin can assist with adult ADHD and anxiety symptoms. Frank Cartwright referenced his own personal transformation through psilocybin and how it had changed his business practice to focus on societal impact and mental health. He reiterated the importance of Silo's current retreat protocols creating a safe, sustainable and accessible container for seekers of this medicine.

Mr. Arnold explained in his statement that the typical retreat has about as much community impact as a group of yoga practitioners. He concluded his written comments with this testimonial from Christopher, a Silo Wellness Jamaican psilocybin retreat participant: "These experiences and interactions have set me on a new trajectory in life. I know my place in this universe, and I owe it to every single person who made it happen."

ABOUT Silo Wellness

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has a presence in both Jamaica and Oregon. Silo Wellness is a publicly traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFD).

For more information about Silo Wellness or to book a Jamaican psilocybin retreat, please visit www.silowellness.com.

Silo Wellness Company Contact:

Mike Arnold, President
541-900-5871
ir@silowellness.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. Forward-looking information may relate to anticipated events or results including, but not limited to the Company successfully launching operations in Oregon under Ballot Measure 109, and the Company's future business plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness's continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130712

News Provided by Newsfile via QuoteMedia

SILO:CNX
Silo Wellness

Silo Wellness


Keep reading...Show less
Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

Silo Wellness Requests Oregon Property Owner Expressions of Interest for Collaborating on Psilocybin Licensing; Other Corporate Updates

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be considering participation in the regulatory regime under Oregon Ballot Measure 109. "With Silo Wellness as the only publicly traded psychedelic company with legal psychedelic retreat experience and a strong connection to Oregon, we believe we are well positioned to collaborate with other Oregonians interested in participating in this burgeoning market," stated Silo Wellness founder and Oregon lawyer Mike Arnold.

"Over the past months we have been touring properties with owners and realtors and have really turned up our search for properties that may be suitable for Oregon psilocybin as we await the final rules from the Oregon Health Authority," Mr. Arnold continued. "However, I also know that there are many property owners who may believe they are sitting on an ideal property for a facility with no interest in selling, but they may not have the legal expertise, network, or capital to make it happen. It is our goal to leverage our platform to help empower Oregonians who may each have a piece of the puzzle - facilitation experience, business experience, property, capital, or a passion for the medicine - and bring them together to help make this industry by Oregonians for Oregonians."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

Silo Wellness Issues Shareholder Letter and Announces New Chief Executive Officer

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, announced today that Silo Wellness founder and chairman of the board of directors Mike Arnold is assuming the role of the Company's interim chief executive officer to continue to lead the Company through its planned acquisition of Dyscovry Science Ltd. and in its planned Oregon psilocybin business objectives. The Company and former CEO Douglas K. Gordon have agreed to Mr. Gordon stepping down as CEO, but he will remain involved in the business, including pursuit of global distribution opportunities for sales of Marley One. During his tenure at Silo Wellness, Mr. Gordon was responsible for the creation of the Marley One global mushroom brand in collaboration with the family of legendary musician Bob Marley and for launching psychedelic retreats in Oregon and Jamaica, a first for a publicly traded company. He also led the Company through its public listing in March of 2021 and two major financings. The Board would like to thank him for his leadership over the past two years.

CEO Mike Arnold founded Silo Wellness in 2018 and was CEO from inception until August 2020. He is an experienced Oregon trial attorney (complex criminal defense and commercial litigation). As the Company's president and chairman of the board of directors, he has been responsible for the Company's Ontario Securities Commission and Canadian Securities Exchange compliance, investor relations, financing, and corporate development. In the last five years he has successfully raised over $12M for his startups.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness to Create a Psychedelic Pharmaceutical Manufacturing and Research Portfolio with Proposed Acquisition of Dyscovry Science

Silo Wellness to Create a Psychedelic Pharmaceutical Manufacturing and Research Portfolio with Proposed Acquisition of Dyscovry Science

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that it has executed a nonbinding letter of intent to acquire 100% of Dyscovry Science Ltd., a Toronto-based biotechnology company. Dyscovry focuses on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition, irritable bowel syndrome. With Dyscovry's research collaboration with Canadian federal government research laboratories, Dyscovry intends to develop a biotechnological process for the production of psilocybin and its potentially novel molecule derivatives.

"We have been working with Brad Dottin and his team at Dyscovry for almost a year now planning this transaction," commented Mike Arnold, Silo Wellness's president and founder. "We have watched the psychedelic market get pummeled as many have been chasing the 'me too' pharma deals, while we stayed focused on preparing for Oregon adult use with a successful Jamaican retreat model while, in the background, working on this unique opportunity. For the first time under one roof, a publicly traded company will provide psychedelic healing right now through Jamaican psychedelic wellness retreats while at the same time innovating the 'what's next' for psychedelic pharmaceutical healing. As an Oregon attorney who founded Silo Wellness in 2018 with the goal of preparing for psilocybin legalization in Oregon, I wanted to ensure that natural psychedelics were never locked up solely behind a pharmacy window controlled by corporations. Our planned acquisition of Dyscovry shows that traditional medicines can coexist alongside modern scientific innovation."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Psychedelics Company Silo Wellness Announces Financing Commitment of CAD$5,950,000 in Convertible Debentures

Psychedelics Company Silo Wellness Announces Financing Commitment of CAD$5,950,000 in Convertible Debentures

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that Alpha Blue Ocean ("ABO"), is supporting the Company's growth with this new CAD$5,950,000 financing arrangement. The Company entered into a subscription agreement (the "Subscription Agreement") with Global Tech Opportunities 14 (the "Subscriber"), that provides for the issuance of convertible debentures (each, a "Convertible Debenture"). The Company intends to use the proceeds to finance manufacturing of the Marley One brand for an existing purchase order and general working capital purposes. The Subscriber is an investment fund managed by Alpha Blue Ocean ("ABO").

"As a publicly-traded psychedelics company offering psychedelics to guests in Jamaica and functional mushroom products across the U.S. and U.K., we welcome this transaction and the opportunity to work with Alpha Blue Ocean," commented Douglas K. Gordon, Silo Wellness's CEO. "This new capital will allow us to strengthen our balance sheet and focus on shareholder value creation through the expansion of our business model and, most directly, the growth of our Marley One line of functional mushroom products."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Silo Wellness Announces Successful Launch of 2022 Psilocybin Retreat Schedule and other Corporate Updates

Silo Wellness Announces Successful Launch of 2022 Psilocybin Retreat Schedule and other Corporate Updates

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, today announces several corporate updates.

On February 4, 2022, the Company completed its first Jamaican psilocybin retreat of 2022 entitled "Renew Your Purpose" (see press release of December 16, 2021). This five-day/four-night psilocybin-assisted retreat was centered around purpose and self-reflection with preparation focusing on themes present in author Jessica Huie's book PURPOSE.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors

Ginkgo Bioworks Appoints Kathy Hopinkah Hannan to its Board of Directors

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced that Kathy Hopinkah Hannan PhD, CPA has joined its Board of Directors, effective August 2, 2022 . Dr. Hannan brings over thirty years of experience as a senior C-Suite executive, corporate advisor, independent board director and strategist leading significant operations and high priority initiatives.

(PRNewsfoto/Ginkgo Bioworks)

"As a pioneer in synthetic biology, Ginkgo Bioworks is undertaking critical work to make biology easier to engineer and to enable a more sustainable future," said Dr. Hannan. "I am honored to join Ginkgo's Board at such a significant time in the company's history, and look forward to working with Ginkgo's incredible team as they use synthetic biology to unlock innovations across industries."

Dr. Hannan is a retired senior partner from KPMG LLP, where she also served as Vice Chair. She brings extensive governance experience through her corporate board roles with Annaly Capital Management, Otis Worldwide Corporation, and Carpenter Technology Corporation, as well as her roles as Chair of the Board of Trustees for the Smithsonian National Museum of the American Indian and formerly as Chair of the Board of Directors of Girl Scouts of the USA . A member of the Ho-Chunk Nation, Dr. Hannan served as a commissioner for the Tribal Employment Rights Office and was a presidential appointee to the National Advisory Council on Indian Education. She also served as a member of the Committee to establish the Board of Directors for the Ho-Chunk Tribe's corporation under Section 17 of the Indian Reorganization Act.

"Dr. Hannan brings invaluable experience as a leader in enterprise sustainability and organizational effectiveness, with an impressive track record for leading key financial and advisory services for clients," said Marijn Dekkers, Chair of the Board of Directors for Ginkgo Bioworks. "Dr. Hannan's industry knowledge and financial acumen is a welcome addition to our Board as Ginkgo continues to grow as a public company. We are looking forward to working with her."

About Ginkgo Bioworks

Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit www.ginkgobioworks.com .

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding Ginkgo's growth and potential innovations. These forward-looking statements generally are identified by the words "believe," "can," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the effect of Ginkgo's business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business and changes in the combined capital structure, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, (vi) the risk of downturns in demand for products using synthetic biology, (vii) the unpredictability of the duration of the COVID-19 pandemic and the demand for COVID-19 testing and the commercial viability of our COVID-19 testing business, and (viii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2022 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com

GINKGO BIOWORKS MEDIA CONTACT:
press@ginkgobioworks.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/ginkgo-bioworks-appoints-kathy-hopinkah-hannan-to-its-board-of-directors-301599762.html

SOURCE Ginkgo Bioworks

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine

GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine

  • GreenLight's messenger RNA production process is transferable to large-scale equipment and CMO facilities​
  • Technology transfer and scale-up from lab bench to Samsung's commercial facility was completed in seven months
  • GreenLight's mRNA synthesis reaction had a titer of 12g/L at a commercial scale and produced 650g of mRNA
  • The mRNA synthesis reaction was achieved without the need for customization, using standard equipment for Contract Development and Manufacturing Companies (CDMO)
  • Commercial-scale run has demonstrated production—in a single facility—of both Drug Substance and LNP formulation, allowing the production of bulk Drug Product

GreenLight Biosciences (Nasdaq: GRNA), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing fully integrated end-to-end contract development and manufacturing services, announced the successful completion of the first commercial-scale engineering run for the companies' mRNA production partnership.

Since the announcement of the strategic partnership between GreenLight Biosciences and Samsung Biologics in late 2021, technology transfer and scale-up from the lab bench to Samsung's commercial facility was completed in seven months, demonstrating platform adaptability and scalability.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants

NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants

GreenLight Biosciences has announced a collaboration with the National Institutes of Health (NIH) to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects.

"This is a tremendous opportunity for us to partner with a premier vaccine discovery team and use our mRNA platform to accelerate the development of coronavirus vaccines which are more broadly protective and durable than those currently available," says Amin Khan, PhD, GreenLight's Chief Science Officer, Human Health.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

Cybin to Present at the Canaccord Genuity 42nd Annual Growth Conference

Cybin Inc. ( NEO:CYBN ) ( NYSE American:CYBN ) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics TM " is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 42 nd Annual Growth Conference being held at the InterContinental Boston Hotel on August 8-11, 2022.

Mr. Drysdale's fireside chat will be webcast live on Thursday, August 11, 2022 at 3:30 p.m. ET. To listen to the event, please click here to access the webcast. The archived webcast will also be available on the Company's investor relations website on the Events & Presentations page.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sharps Compliance Corp. , Infrastructure and Energy Alternatives, Inc. , AutoWeb, Inc. , Zymergen Inc.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sharps Compliance Corp. , Infrastructure and Energy Alternatives, Inc. , AutoWeb, Inc. , Zymergen Inc.

Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( jbrodsky@brodskysmith.com ) or Marc Ackerman ( mackerman@brodskysmith.com ) at 855-576-4847. There is no cost or financial obligation to you.

Infrastructure and Energy Alternatives, Inc. (Nasdaq - IEA)

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cybin Announces Date of Annual Meeting of Shareholders

Cybin Announces Date of Annual Meeting of Shareholders

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (" Cybin " or the " Company "), a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics TM " announced today that its 2022 Annual Meeting of Shareholders will be held virtually on Monday, August 15, 2022 at 10:00 a.m. ET.

The notice of annual meeting and proxy statement containing meeting details are expected to be available on or about July 25, 2022 to shareholders of record as of the close of business on July 11, 2022. Meeting materials will be mailed and also made available under the Company's profile on SEDAR at www.sedar.com , and on the Company's website at www.cybin.com .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×